Cargando…

Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials

Detalles Bibliográficos
Autores principales:	Alecu, Iulian, Milenkova, Tsveta, Turner, Simon R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826089/ https://www.ncbi.nlm.nih.gov/pubmed/29505040 http://dx.doi.org/10.2147/DDDT.S156746

Ejemplares similares

Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials
por: Zhou, Jian xin, et al.
Publicado: (2017)

Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy
por: Chen, Zheling, et al.
Publicado: (2021)

Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer
por: Yordanova, Mariya, et al.
Publicado: (2021)

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
por: Teyssonneau, Diego, et al.
Publicado: (2022)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
por: Wilson, Zena, et al.
Publicado: (2022)

RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors
por: Roulston, Anne, et al.
Publicado: (2022)

PARP-1 inhibitor monotherapy and combination therapy in a preclinical mouse model of Brca2 mutant breast cancer
por: Hay, T, et al.
Publicado: (2008)

Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors
por: Plummer, Ruth, et al.
Publicado: (2014)

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
por: Shu, Yamin, et al.
Publicado: (2022)

Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE
por: Gooderham, Melinda J., et al.
Publicado: (2021)

PARP inhibitor combinations in prostate cancer
por: Pezaro, Carmel
Publicado: (2020)

Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials
por: Bowling, Gartrell C., et al.
Publicado: (2023)

Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy
por: Cone, Eugene B., et al.
Publicado: (2022)

Advances in using PARP inhibitors to treat cancer
por: Kummar, Shivaani, et al.
Publicado: (2012)

Strategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced Cytotoxicity
por: Horton, Julie K., et al.
Publicado: (2013)

PARP inhibitors: current status and implications for anticancer therapeutics
por: Usmani, Hadi, et al.
Publicado: (2013)

PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
por: Barcellini, Amelia, et al.
Publicado: (2021)

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
por: Bonadio, Renata Colombo, et al.
Publicado: (2021)

PARP inhibitors combined with radiotherapy: are we ready?
por: Sun, Chen, et al.
Publicado: (2023)

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma
por: Gill, Sonja J., et al.
Publicado: (2015)

Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling
por: Smith, Hannah L., et al.
Publicado: (2022)

PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
por: Bian, X, et al.
Publicado: (2018)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumab
por: Hata, Akito, et al.
Publicado: (2018)

Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies
por: Labrie, Marilyne, et al.
Publicado: (2021)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020)

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1
por: Fiskus, Warren, et al.
Publicado: (2022)

Combining enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness
por: Thompson, Timothy C., et al.
Publicado: (2017)

The role of PARP inhibitor combination therapy in ovarian cancer
por: Hockings, Helen, et al.
Publicado: (2023)

Combination Treatment Strategies to Overcome PARP Inhibitor Resistance
por: Soung, Young-Hwa, et al.
Publicado: (2023)

PARP inhibitors: enhancing efficacy through rational combinations
por: Bhamidipati, Deepak, et al.
Publicado: (2023)

Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Wang, Hongmei, et al.
Publicado: (2021)

PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016)

VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
por: Bizzaro, Francesca, et al.
Publicado: (2021)

Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
por: Vikas, Praveen, et al.
Publicado: (2020)

PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
por: Miller, Rowan E, et al.
Publicado: (2022)

Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
por: Tang, Bin, et al.
Publicado: (2023)

An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
por: Xu, Jing, et al.
Publicado: (2022)

Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (Review)
por: Jin, Ning, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ogvoieuvah2gnvaglfcmk5ju9c